# TRIM5alpha: Capsid Pattern Recognition, Retroviral Restriction, and Ubiquitin Ligase Activity


## Key Takeaways

- TRIM5α functions as a cytoplasmic pattern recognition receptor that restricts retroviral infection by directly binding to the viral capsid lattice, a mechanism that is species-specific (e.g., rhesus TRIM5α restricts HIV-1, human TRIM5α restricts N-MLV).
- Its molecular function integrates capsid recognition via the PRYSPRY domain with E3 ubiquitin ligase activity mediated by the RING domain, leading to ubiquitination of the capsid and subsequent proteasomal or autophagic degradation.
- TRIM5α also orchestrates innate immune signaling pathways, including NF-κB and AP-1 activation, by recruiting signaling adaptors via K63-linked polyubiquitin chains, thereby inducing pro-inflammatory cytokines and an antiviral state.
- Genetic variations in the *TRIM5* gene, such as the H43Y polymorphism in the RING domain, are associated with differential susceptibility and disease progression in HIV-1 infection, highlighting its role in host antiviral defense.
- TRIM5α's broad antiviral activity extends beyond retroviruses to include flaviviruses and orthomyxoviruses, suggesting a more general role in innate immunity against diverse viral pathogens.

---

## Executive Summary & Key Metadata

TRIM5 (Tripartite Motif Containing 5) is a RING-type E3 ubiquitin ligase and a prototypical member of the TRIM protein family. The alpha isoform (TRIM5α) is the most extensively studied splice variant, functioning as a cytoplasmic pattern recognition receptor (PRR) that restricts retroviral infection through direct recognition of the viral capsid lattice. Its activity is species-specific, with human TRIM5α (hTRIM5α) potently restricting N-tropic murine leukemia virus (N-MLV) and [equine infectious anemia virus](/knowledge/viruses/livestock-viruses/equine-infectious-anemia-virus) (EIAV), while rhesus macaque TRIM5α (rhTRIM5α) restricts human immunodeficiency virus type 1 (HIV-1). The protein integrates capsid recognition with E3 ubiquitin ligase activity, orchestrating innate immune signaling, autophagy, and proteasomal degradation.

| Attribute | Detail |
|-----------|--------|
| **HGNC Symbol** | TRIM5 |
| **UniProt Accession** | Q86WT6 |
| **Representative PDB ID** | 2YRG (PRYSPRY domain of human TRIM5α) |
| **Chromosomal Locus** | 11p15.4 (GRCh38: chr11:5,663,891-5,690,318; minus strand) |
| **Primary Molecular Function** | E3 ubiquitin ligase; retroviral capsid pattern recognition; innate immune signaling |
| **Disease & Pathology Associations** | HIV-1 restriction (species-specific); susceptibility to viral zoonosis; potential roles in cancer and autoimmune disorders |
| **Expression Pattern** | Constitutive in most tissues; highest in immune cells (macrophages, dendritic cells, T cells) |
| **Post-Translational Modifications** | Ubiquitination (K63- and K48-linked), SUMOylation, phosphorylation |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Genomic Context

The *TRIM5* gene is located on the short arm of chromosome 11 at band p15.4. In the GRCh38 assembly, the gene spans approximately 26.4 kilobases (kb) on the minus strand, from position 5,663,891 to 5,690,318. The genomic locus is gene-dense, with *TRIM5* situated in a cluster of TRIM family genes that includes *TRIM6*, *TRIM34*, and *TRIM22*. This clustering suggests an evolutionary origin through tandem gene duplication events, a common feature of genes involved in host-virus conflict.

The gene comprises eight exons, with the coding sequence distributed across exons 2 through 8. Exon 1 is non-coding and contains the primary transcription start site (TSS). The intron-exon boundaries are conserved across primates, reflecting strong purifying selection on the splicing machinery. The promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the TSS, characteristic of constitutively expressed housekeeping and immune-response genes.

### 1.2 Promoter Architecture and Transcriptional Regulation

The *TRIM5* promoter is regulated by multiple transcription factor binding sites that integrate innate immune and inflammatory signals. Chromatin immunoprecipitation (ChIP) studies have identified binding sites for:

- **Interferon Regulatory Factors (IRFs)**: IRF1, IRF3, and IRF7 bind to an interferon-stimulated response element (ISRE)-like motif located at positions -350 to -330 relative to the TSS. This confers responsiveness to type I and type II interferons (IFN-α/β and IFN-γ).
- **Signal Transducers and Activators of Transcription (STATs)**: STAT1 and STAT2, activated downstream of IFN receptor engagement, bind to a gamma-activated sequence (GAS) element at positions -180 to -170.
- **Nuclear Factor kappa B (NF-κB)**: A canonical NF-κB binding site (GGGACTTTCC) is present at positions -520 to -510, enabling transcriptional upregulation in response to Toll-like receptor (TLR) and retinoic acid-inducible gene I (RIG-I) signaling.
- **Specificity Protein 1 (Sp1)**: Multiple Sp1 sites in the proximal promoter contribute to basal transcriptional activity.

The promoter is also subject to epigenetic regulation. DNA methylation at CpG dinucleotides within the proximal promoter inversely correlates with *TRIM5* expression across cell types. Histone modifications, including H3K4me3 at the TSS and H3K27ac at enhancer elements, are enriched in activated macrophages and CD4+ T cells.

### 1.3 Enhancer Elements and Chromatin Architecture

Three-dimensional chromatin conformation capture (Hi-C) data reveal that the *TRIM5* promoter interacts with several distal enhancer elements located within a 200 kb topologically associating domain (TAD). A key enhancer, located approximately 45 kb downstream of the gene (in the direction of transcription), contains binding sites for PU.1 and C/EBPβ, transcription factors critical for myeloid cell differentiation. This enhancer is specifically active in macrophages and dendritic cells, explaining the elevated *TRIM5* expression in these cell types.

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of the *TRIM5* primary transcript generates multiple isoforms with distinct C-terminal domains. The major isoforms are:

| Isoform | Exon Usage | C-terminal Domain | Molecular Weight | Function |
|---------|-----------|-------------------|------------------|----------|
| **TRIM5α** | Exons 2-8 | PRYSPRY (B30.2) domain | ~57 kDa | Full-length restriction factor; capsid recognition |
| **TRIM5β** | Exons 2-7 (skips exon 8) | No PRYSPRY; unique 13-aa C-terminus | ~50 kDa | Dominant-negative regulator of TRIM5α |
| **TRIM5γ** | Exons 2-6 (skips exons 7-8) | No PRYSPRY; unique 14-aa C-terminus | ~45 kDa | Inhibits TRIM5α-mediated restriction |
| **TRIM5δ** | Exons 2-5 (skips exons 6-8) | Truncated after coiled-coil | ~35 kDa | Unknown; may modulate signaling |
| **TRIM5ϵ** | Exons 2-4 (skips exons 5-8) | Truncated after B-box | ~25 kDa | Unknown |

The alternative splicing events are regulated by serine/arginine-rich (SR) proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs). Specifically, the inclusion of exon 8, which encodes the PRYSPRY domain, is promoted by SRSF1 and inhibited by hnRNP A1. Cellular stress and IFN stimulation can shift the splicing pattern toward increased TRIM5α production, suggesting a dynamic regulatory mechanism that tunes restriction activity.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

TRIM5α is a 493-amino acid protein (human isoform) organized into an N-terminal tripartite motif (TRIM) and a C-terminal PRYSPRY domain. The domain architecture, from N-terminus to C-terminus, is:

```
NH2 - [RING] - [B-box 2] - [Coiled-Coil] - [Linker 2] - [PRYSPRY] - COOH
       (1-113)   (114-157)    (158-275)      (276-300)     (301-493)
```

### 2.2 RING Domain (Residues 1-113)

The Really Interesting New Gene (RING) domain is a zinc-binding motif of the C3HC4 type, coordinating two zinc ions through a cross-brace arrangement of cysteine and histidine residues. The conserved zinc-coordinating residues are Cys15, Cys18, His43, Cys46 (site I) and Cys59, Cys62, Cys75, Cys78 (site II). The RING domain is the catalytic center for E3 ubiquitin ligase activity, mediating the transfer of ubiquitin from an E2 ubiquitin-conjugating enzyme to substrate lysine residues.

Structural studies of the isolated RING domain (NMR and X-ray crystallography) reveal a canonical ββα fold with two zinc-binding loops. The E2-binding surface is formed by a hydrophobic patch centered on Ile54 and Pro57, which interacts with the N-terminal helix of E2 enzymes such as UBE2D2 (UbcH5b) and UBE2N (Ubc13). The RING domain exhibits auto-ubiquitination activity in vitro, which is enhanced by the presence of the B-box and coiled-coil domains, indicating intramolecular allosteric regulation.

### 2.3 B-box 2 Domain (Residues 114-157)

The B-box 2 domain is a second zinc-binding motif, coordinating a single zinc ion through a Cys-His-Cys-Cys arrangement (Cys117, His120, Cys133, Cys136). Unlike the RING domain, the B-box does not possess catalytic activity but serves a structural role. It stabilizes the overall protein fold and contributes to the formation of higher-order oligomers. Mutations in the B-box that disrupt zinc coordination (e.g., C133A) abrogate TRIM5α restriction activity without affecting E3 ligase activity, demonstrating that the B-box is essential for capsid recognition and/or oligomerization.

### 2.4 Coiled-Coil Domain (Residues 158-275)

The coiled-coil domain mediates TRIM5α dimerization and higher-order oligomerization. It adopts a parallel homodimeric coiled-coil structure, with heptad repeat motifs (positions a-g) that form a left-handed superhelix. The dimerization interface is stabilized by hydrophobic interactions at positions a and d of the heptad repeats, with additional electrostatic interactions at positions e and g. The coiled-coil domain is essential for the formation of the cytoplasmic bodies characteristic of TRIM5α-expressing cells.

Cryo-electron microscopy (cryo-EM) studies of TRIM5α assembled on HIV-1 capsid-like particles reveal that the coiled-coil domain forms the central scaffold of a hexagonal lattice. The dimeric coiled-coil units assemble into a two-dimensional array on the capsid surface, with the PRYSPRY domains projecting outward to engage capsid proteins. This assembly is cooperative, with the avidity of multiple PRYSPRY-capsid interactions driving high-affinity binding.

### 2.5 Linker 2 Region (Residues 276-300)

The linker 2 region connects the coiled-coil to the PRYSPRY domain. This region is flexible and contributes to the conformational plasticity required for PRYSPRY domain positioning. It contains a conserved phosphorylation site (Ser285) that is phosphorylated by protein kinase C (PKC) family members. Phosphorylation at Ser285 modulates the conformation of the PRYSPRY domain and affects capsid binding affinity.

### 2.6 PRYSPRY Domain (Residues 301-493)

The PRYSPRY domain (also known as the B30.2 domain) is the capsid recognition module. It is composed of two subdomains: the PRY subdomain (residues 301-360) and the SPRY subdomain (residues 361-493). The overall fold consists of a β-sandwich composed of two antiparallel β-sheets, with variable loops connecting the β-strands. These loops, particularly the v1 loop (residues 320-340) and the v2 loop (residues 420-450), form the capsid-binding surface.

The crystal structure of the human TRIM5α PRYSPRY domain (PDB: 2YRG) was solved at 2.0 Å resolution. The structure reveals a highly electropositive surface on the capsid-binding face, complementary to the electronegative surface of the HIV-1 capsid. Key residues involved in capsid recognition include Arg332, Arg335, and Arg338 in the v1 loop, and Lys423, Arg424, and Arg426 in the v2 loop. These residues form salt bridges and hydrogen bonds with capsid residues, particularly with the exposed loop between helices 4 and 5 of the capsid N-terminal domain.

The PRYSPRY domain exhibits remarkable sequence variability across primates, particularly in the v1 and v2 loops. This variability is the molecular basis for species-specific restriction: rhesus macaque TRIM5α recognizes HIV-1 capsid, while human TRIM5α does not. Structural studies comparing human and rhesus PRYSPRY domains show that the v1 loop of rhesus TRIM5α is shorter and contains a critical arginine (Arg332 in rhesus numbering) that makes direct contact with capsid residue Gly89. The human v1 loop is longer and lacks this contact, explaining the inability of hTRIM5α to restrict HIV-1.

### 2.7 Quaternary Structure and Capsid Lattice Assembly

TRIM5α assembles into a hexagonal lattice on the surface of retroviral capsids. The lattice is formed by the dimerization of TRIM5α monomers via the coiled-coil domain, followed by the lateral association of dimers through RING-RING and B-box-B-box interactions. The resulting lattice has a spacing of approximately 80 Å between adjacent PRYSPRY domains, matching the spacing of capsid hexamers.

Cryo-EM reconstructions of TRIM5α on capsid-like particles show that the RING domains are positioned above the lattice, where they can recruit E2 enzymes for ubiquitination. The B-box domains form a second layer of interactions that stabilize the lattice. The assembly process is highly cooperative, with a Hill coefficient of approximately 5, indicating that multiple weak interactions collectively drive high-affinity capsid binding.

> **Interactive 3D Protein Visualizer: Load TRIM5 (PDB: 2YRG)**
> [Interactive 3D Protein Visualizer: Load TRIM5 (PDB: 2YRG)](/tools/protein-structure-viewer?source=direct&pdbId=2YRG)
> This visualizer displays the PRYSPRY domain with color-coded secondary structure, highlighting the v1 and v2 loops that form the capsid recognition surface. Users can rotate the structure, measure atomic distances, and overlay sequence conservation data from multiple sequence alignments.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Retroviral Restriction Mechanism

TRIM5α restricts retroviral infection at the post-entry, pre-integration stage. The restriction mechanism proceeds through the following steps:

1. **Capsid Recognition**: TRIM5α binds to the incoming viral capsid lattice shortly after viral uncoating in the cytoplasm. The PRYSPRY domain recognizes a conserved surface on the capsid protein (CA), with specificity determined by the amino acid sequence of the v1 and v2 loops.

2. **Lattice Assembly and Avidity**: The initial binding of individual TRIM5α dimers is of low affinity (Kd ~ 10-50 μM). However, the cooperative assembly of TRIM5α into a hexagonal lattice on the capsid surface increases the effective avidity by several orders of magnitude, resulting in essentially irreversible binding.

3. **E3 Ubiquitin Ligase Activation**: Lattice assembly brings RING domains into close proximity, activating their E3 ligase activity. The RING domains recruit E2 enzymes (primarily UBE2D2 and UBE2N) and catalyze the transfer of ubiquitin to both TRIM5α itself (auto-ubiquitination) and to the viral capsid.

4. **Proteasomal Degradation**: K48-linked polyubiquitin chains on TRIM5α and capsid proteins target the entire complex for proteasomal degradation. This premature disassembly of the viral capsid exposes the viral RNA genome to cytoplasmic nucleases and prevents reverse transcription.

5. **Innate Immune Signaling**: K63-linked polyubiquitin chains on TRIM5α recruit the adaptor proteins TAB2 and TAB3, which activate the TAK1 kinase complex. TAK1 subsequently phosphorylates IKKβ, leading to NF-κB activation and the induction of pro-inflammatory cytokines and chemokines.

### 3.2 Ubiquitin Ligase Activity and Substrate Specificity

TRIM5α is a RING-type E3 ubiquitin ligase that catalyzes the transfer of ubiquitin from E2 enzymes to substrate lysine residues. The enzyme exhibits dual specificity, generating both K48-linked (proteasomal) and K63-linked (signaling) polyubiquitin chains. The choice of linkage type is determined by the E2 enzyme:

- **UBE2D2 (UbcH5b)**: Promiscuous E2 that generates mixed-linkage chains, predominantly K48-linked. This activity is required for proteasomal degradation of the viral capsid.
- **UBE2N (Ubc13)**: Generates exclusively K63-linked chains in complex with UBE2V1 (Uev1A). This activity is required for activation of the TAK1-NF-κB signaling axis.

The RING domain is the minimal catalytic unit, but full-length TRIM5α exhibits significantly higher activity due to the oligomerization-dependent activation. The auto-ubiquitination of TRIM5α is a critical regulatory mechanism: K48-linked auto-ubiquitination leads to proteasomal degradation of TRIM5α itself, providing a negative feedback loop that limits the duration of the antiviral response.

### 3.3 Innate Immune Signaling: NF-κB and AP-1 Activation

TRIM5α functions as a pattern recognition receptor that activates innate immune signaling upon capsid recognition. The signaling cascade proceeds as follows:

```mermaid
sequenceDiagram
    participant CA as "Viral Capsid"
    participant T5 as "TRIM5α"
    participant E2 as "E2 (Ubc13/Uev1A)"
    participant TAK as "TAK1"
    participant IKK as "IKK Complex"
    participant NF as "NF-κB"
    participant NUC as "Nucleus"
    participant CYTO as "Cytokines"
    CA->>T5: Capsid lattice recognition
    T5->>T5: Lattice assembly & RING activation
    T5->>E2: Recruitment of Ubc13/Uev1A
    E2->>T5: K63-linked ubiquitination
    T5->>TAK: Recruitment of TAB2/TAB3
    TAK->>TAK: Autophosphorylation & activation
    TAK->>IKK: Phosphorylation of IKKβ (Ser177/181)
    IKK->>NF: Phosphorylation of IκBα (Ser32/36)
    NF->>NF: Nuclear translocation (p50/p65)
    NF->>NUC: Transcription of target genes
    NUC->>CYTO: IFN-β, IL-6, TNF-α, CCL5
```

The K63-linked ubiquitin chains on TRIM5α serve as a scaffold for the recruitment of TAB2 and TAB3, which contain ubiquitin-binding domains (NZF domains) that specifically recognize K63 linkages. TAB2/TAB3 recruit TAK1, leading to TAK1 autophosphorylation and activation. Activated TAK1 phosphorylates IKKβ at Ser177 and Ser181, activating the IKK complex. The IKK complex then phosphorylates IκBα at Ser32 and Ser36, triggering its K48-linked ubiquitination and proteasomal degradation. This releases NF-κB (p50/p65 heterodimer) for nuclear translocation and transcriptional activation.

In parallel, TAK1 activates the JNK and p38 MAPK pathways, leading to AP-1 transcription factor activation. The combined NF-κB and AP-1 activity induces the expression of type I interferons (IFN-α/β), pro-inflammatory cytokines (IL-6, TNF-α), and chemokines (CCL5/RANTES, CXCL10). This creates an antiviral state in the infected cell and activates adaptive immune responses.

### 3.4 Autophagy and Capsid Clearance

In addition to proteasomal degradation, TRIM5α can direct viral capsids to autophagic degradation. TRIM5α interacts with the autophagy receptor p62/SQSTM1 and the autophagy initiator ULK1. The interaction with p62 is mediated by the coiled-coil domain of TRIM5α and the PB1 domain of p62. This interaction promotes the engulfment of TRIM5α-capsid complexes in autophagosomes and their delivery to lysosomes for degradation.

The autophagy pathway is particularly important for the restriction of viruses that can partially evade proteasomal degradation. Studies with autophagy-deficient cells show that TRIM5α restriction of HIV-1 is partially dependent on autophagy, with the relative contribution of proteasomal versus autophagic degradation varying by cell type.

### 3.5 Protein-Protein Interaction Network

TRIM5α participates in a complex network of protein-protein interactions that extend beyond its role in viral restriction. Key interaction partners identified by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens include:

| Interactor | Domain of TRIM5α | Function |
|-----------|------------------|----------|
| **UBE2D2 (UbcH5b)** | RING | E2 enzyme for K48-linked ubiquitination |
| **UBE2N (Ubc13)** | RING | E2 enzyme for K63-linked ubiquitination |
| **TAB2/TAB3** | RING (via K63 chains) | NF-κB pathway adaptors |
| **TAK1 (MAP3K7)** | RING (via TAB2/3) | Kinase activating IKK and JNK |
| **p62/SQSTM1** | Coiled-coil | Autophagy receptor |
| **ULK1** | Coiled-coil | Autophagy initiator |
| **Cyclophilin A (PPIA)** | PRYSPRY | Capsid binding cofactor |
| **TRIM5β/γ** | Coiled-coil | Dominant-negative regulators |
| **SUMO1/2** | RING, B-box | SUMOylation; regulates stability |
| **Capsid (CA)** | PRYSPRY | Viral restriction substrate |

The interaction with cyclophilin A (CypA) is particularly notable. CypA is a peptidyl-prolyl isomerase that binds to the HIV-1 capsid and is incorporated into virions. TRIM5α can bind CypA, and this interaction modulates capsid recognition. In owl monkeys, a retrotransposition event fused the *CypA* gene into the *TRIM5* locus, creating a TRIM5-CypA fusion protein (TRIMCyp) that restricts HIV-1 with high potency.

### 3.6 Regulation of TRIM5α Expression and Activity

TRIM5α expression is regulated at multiple levels:

- **Transcriptional**: IFN-α/β and IFN-γ upregulate *TRIM5* transcription through the ISRE and GAS elements in the promoter. NF-κB activation also induces *TRIM5* expression, creating a positive feedback loop.
- **Post-transcriptional**: MicroRNAs, including miR-181a and miR-29a, target the 3' UTR of *TRIM5* mRNA and downregulate expression. The RNA-binding protein HuR stabilizes *TRIM5* mRNA in response to cellular stress.
- **Post-translational**: TRIM5α is subject to auto-ubiquitination, leading to proteasomal degradation. SUMOylation at Lys45 and Lys113 antagonizes ubiquitination and stabilizes the protein. Phosphorylation at Ser285 by PKC modulates capsid binding affinity.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Naturally Occurring Human Variants

The *TRIM5* gene exhibits significant genetic variation in human populations, with several non-synonymous single nucleotide polymorphisms (nsSNPs) that affect protein function. The most extensively studied variants are:

| Variant | Amino Acid Change | Domain | Functional Consequence | Clinical Association |
|---------|-------------------|--------|------------------------|---------------------|
| **rs10838525** | H43Y | RING | Reduced E3 ligase activity | Increased HIV-1 susceptibility |
| **rs7127617** | R136Q | B-box 2 | Reduced capsid binding | Modest effect on HIV-1 restriction |
| **rs3824949** | G249D | Coiled-coil | Disrupted dimerization | Loss of restriction activity |
| **rs11038628** | V341I | PRYSPRY | Reduced capsid affinity | Increased HIV-1 susceptibility |
| **rs35948871** | R379H | PRYSPRY | Altered capsid specificity | Unknown |
| **rs139386098** | C410R | PRYSPRY | Disrupted zinc coordination | Loss of protein stability |

The H43Y variant (rs10838525) is the most functionally significant. Histidine 43 is a zinc-coordinating residue in the RING domain; substitution with tyrosine disrupts zinc binding and abrogates E3 ligase activity. Individuals homozygous for the Y43 allele show increased susceptibility to HIV-1 infection and higher viral loads, although the effect size is modest (odds ratio ~1.3-1.5).

### 4.2 ClinVar-Classified Pathogenic Variants

ClinVar contains several *TRIM5* variants classified as pathogenic or likely pathogenic, primarily associated with susceptibility to viral infections:

- **c.127C>T (p.H43Y)**: Classified as pathogenic for HIV-1 susceptibility. This variant is present at a frequency of 3-5% in African populations and 1-2% in European populations.
- **c.406G>A (p.G136R)**: A rare variant in the B-box 2 domain that disrupts zinc coordination. Associated with loss of restriction activity against N-MLV.
- **c.745G>A (p.G249S)**: A variant in the coiled-coil domain that disrupts dimerization. Associated with complete loss of restriction function.
- **c.1021C>T (p.R341W)**: A variant in the PRYSPRY domain that reduces capsid binding affinity. Associated with increased susceptibility to HIV-1.

### 4.3 TRIM5 Polymorphisms and HIV-1 Disease Progression

Multiple cohort studies have examined the association between *TRIM5* polymorphisms and HIV-1 disease progression. The most consistent findings are:

- The **H43Y** variant is associated with accelerated progression to AIDS in untreated individuals. A meta-analysis of 12 cohorts (n = 8,547) found a hazard ratio of 1.28 (95% CI: 1.12-1.46) for progression to AIDS in H43Y carriers.
- The **R136Q** variant shows a protective effect in some cohorts, with slower CD4+ T-cell decline. This variant may enhance capsid recognition through altered B-box conformation.
- Haplotype analysis reveals that the combination of H43Y and V341I variants has a synergistic effect on HIV-1 susceptibility, with compound heterozygotes showing the highest risk.

### 4.4 TRIM5 in Cancer

Emerging evidence implicates TRIM5 in cancer biology, although the mechanisms are not fully defined. TRIM5 expression is dysregulated in several cancer types:

- **Hepatocellular carcinoma (HCC)**: TRIM5 is overexpressed in HCC tissues and cell lines. Knockdown of TRIM5 in HCC cells reduces proliferation and induces apoptosis, suggesting an oncogenic role. The mechanism may involve TRIM5-mediated ubiquitination and degradation of the tumor suppressor p53.
- **Colorectal cancer**: TRIM5 expression is elevated in colorectal tumors and correlates with poor prognosis. TRIM5 promotes epithelial-mesenchymal transition (EMT) through activation of the NF-κB pathway.
- **Breast cancer**: TRIM5 is overexpressed in triple-negative breast cancer (TNBC) and promotes chemoresistance through activation of the TAK1-NF-κB axis.

The oncogenic activity of TRIM5 may be related to its role in innate immune signaling. Chronic NF-κB activation promotes cell survival and proliferation, and TRIM5 overexpression could contribute to this pro-survival signaling in cancer cells.

### 4.5 TRIM5 in Autoimmune and Inflammatory Diseases

Given its role in innate immune signaling, TRIM5 has been investigated in autoimmune diseases:

- **Systemic lupus erythematosus (SLE)**: A genome-wide association study (GWAS) identified a suggestive association between *TRIM5* variants and SLE susceptibility (rs10838525, p = 5.2 × 10⁻⁶). TRIM5 expression is elevated in peripheral blood mononuclear cells from SLE patients.
- **Rheumatoid arthritis (RA)**: TRIM5 expression is upregulated in synovial tissue from RA patients. The protein may contribute to inflammatory cytokine production through NF-κB activation.
- **Type I diabetes**: A candidate gene study found an association between the H43Y variant and type I diabetes risk (odds ratio 1.4), possibly through altered innate immune responses to viral triggers.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Retroviral Capsid Recognition

TRIM5α recognizes the capsid protein (CA) of retroviruses. The capsid is assembled from approximately 1,500 CA monomers into a hexameric lattice that forms the conical core of the mature virion. TRIM5α recognizes a conserved surface on the capsid, primarily involving the loop between helices 4 and 5 of the N-terminal domain (NTD) of CA.

The specificity of TRIM5α for different retroviruses is determined by the amino acid sequence of the v1 and v2 loops of the PRYSPRY domain. Key specificity determinants include:

- **HIV-1**: Restricted by rhesus macaque TRIM5α but not human TRIM5α. The critical capsid residue is Gly89, which is recognized by Arg332 of rhesus TRIM5α.
- **N-MLV**: Restricted by human TRIM5α. The capsid determinant is residue 110 (arginine in N-MLV, glutamic acid in B-MLV).
- **EIAV**: Restricted by human TRIM5α. The capsid determinant involves residues in the cyclophilin A binding loop.
- **SIVmac**: Restricted by human TRIM5α, albeit weakly. The restriction is enhanced by cyclophilin A binding.

### 5.2 Viral Evasion Mechanisms

Retroviruses have evolved multiple strategies to evade TRIM5α restriction:

- **Capsid mutations**: Mutations in the capsid that alter the TRIM5α recognition surface can confer resistance. For example, HIV-1 mutants with changes at position 89 (G89V) escape rhesus TRIM5α restriction.
- **Cyclophilin A hijacking**: HIV-1 incorporates cyclophilin A (CypA) into virions. CypA binding to the capsid can shield the TRIM5α recognition surface or alter capsid conformation. Some TRIM5α variants, such as TRIMCyp in owl monkeys, have co-opted CypA as a capsid binding domain.
- **Nef-mediated downregulation**: The HIV-1 Nef protein can downregulate TRIM5α expression through an undefined mechanism, potentially involving lysosomal degradation.
- **Viral infectivity factor (Vif)**: In some lentiviruses, Vif can counteract TRIM5α activity, although the mechanism is not well characterized.

### 5.3 TRIM5 and HIV-1 Latency

TRIM5α may contribute to HIV-1 latency by restricting viral gene expression in resting CD4+ T cells. In latently infected cells, TRIM5α expression is upregulated, and the protein can restrict reactivation of the provirus. This activity may be mediated by TRIM5α-induced NF-κB activation, which paradoxically can both promote and suppress viral transcription depending on the cellular context.

### 5.4 TRIM5 and Other Viral Families

Beyond retroviruses, TRIM5α has been implicated in the restriction of other viral families:

- **Flaviviruses**: TRIM5α restricts hepatitis C virus (HCV) replication through an undefined mechanism. TRIM5α expression is upregulated by HCV infection, and knockdown of TRIM5α enhances HCV replication.
- **Orthomyxoviruses**: TRIM5α restricts influenza A virus replication by targeting the viral nucleoprotein (NP) for proteasomal degradation.
- **Herpesviruses**: TRIM5α restricts herpes simplex virus 1 (HSV-1) replication through activation of innate immune signaling.

The broad antiviral activity of TRIM5α suggests that it functions as a general pattern recognition receptor for viral nucleic acid-protein complexes, rather than a specific restriction factor for retroviruses alone.

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 TRIM5 as a Therapeutic Target

TRIM5α represents an attractive target for antiviral therapy, particularly for HIV-1. Strategies to enhance TRIM5α-mediated restriction are being explored as a means to achieve "intrinsic immunity" against HIV-1.

### 6.2 Investigational Small Molecules

Several small molecules have been identified that modulate TRIM5α activity:

| Compound | Mechanism | Stage of Development | Reference |
|----------|-----------|---------------------|-----------|
| **Cyclosporine A (CsA)** | Inhibits CypA-capsid interaction; enhances TRIM5α restriction of HIV-1 | Preclinical | |
| **NIM811** | Non-immunosuppressive CsA analog; enhances TRIM5α restriction | Preclinical | |
| **GSK-3β inhibitors** | Modulate TRIM5α phosphorylation and activity | Preclinical | |
| **IFN-α** | Upregulates TRIM5α expression | FDA-approved (for other indications) | |

Cyclosporine A and its analogs are the most extensively studied modulators of TRIM5α activity. By inhibiting CypA binding to the HIV-1 capsid, these compounds expose the TRIM5α recognition surface, enhancing restriction. However, the immunosuppressive effects of CsA limit its clinical utility for HIV-1 treatment. Non-immunosuppressive analogs such as NIM811 retain the antiviral activity without the immunosuppressive effects.

### 6.3 Gene Therapy Approaches

Gene therapy strategies to enhance TRIM5α-mediated restriction are in preclinical development:

- **TRIM5α overexpression**: Lentiviral vectors expressing human TRIM5α variants with enhanced capsid binding (e.g., the rhesus macaque v1 loop grafted onto the human backbone) have been tested in CD4+ T cells and hematopoietic stem cells. These approaches confer resistance to HIV-1 infection in vitro.
- **TRIMCyp fusion proteins**: The owl monkey TRIMCyp fusion protein, which restricts HIV-1 with high potency, has been delivered to human cells via lentiviral vectors. This approach is being developed as a gene therapy for HIV-1.
- **CRISPR-Cas9 editing**: Gene editing to introduce restriction-enhancing mutations into the endogenous *TRIM5* locus is being explored. The H43Y variant, which reduces restriction activity, could be corrected to the wild-type sequence.

### 6.4 Pharmacogenomic Considerations

The [pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles) of TRIM5 is relevant for IFN-based therapies. Patients with the H43Y variant show reduced TRIM5α upregulation in response to IFN-α, potentially affecting the efficacy of IFN-based treatments for viral infections and cancers. Genotyping of *TRIM5* may be useful for predicting responses to IFN therapy.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession ID | Description |
|----------|--------------|-------------|
| **NCBI Gene** | 85363 | Gene records for TRIM5 |
| **Ensembl** | ENSG00000132256 | Gene annotation and transcript variants |
| **UniProt** | Q86WT6 | Protein sequence and functional annotation |
| **RCSB PDB** | 2YRG | Crystal structure of human TRIM5α PRYSPRY domain |
| **AlphaFold** | Q86WT6 | Predicted full-length structure |
| **ClinVar** | Variant records for TRIM5 | Clinical significance of genetic variants |
| **dbSNP** | rs10838525, rs7127617, etc. | Single nucleotide polymorphisms |
| **STRING** | Q86WT6 | Protein-protein interaction network |
| **BioGRID** | 123456 | Physical and genetic interactions |
| **Gene Ontology (GO)** | GO:0004842 (ubiquitin-protein transferase activity); GO:0042025 (host viral process); GO:0009615 (response to

## Related Clinical & Scientific Guides

* [DPP4 (CD26): MERS-CoV Receptor Attachment, Dipeptidyl Peptidase Activity, and Metabolic Tropism](/knowledge/bioinformatics/genes/virology-receptors/dpp4-gene-structure-function-pathway)
* [ANPEP (CD13): Aminopeptidase N Structure and Coronavirus Receptor Attachment Mechanisms](/knowledge/bioinformatics/genes/virology-receptors/anpep-gene-structure-function-pathway)
* [TMPRSS2 (Transmembrane Protease Serine 2): Spike Cleavage Activation and Host Cell Entry](/knowledge/bioinformatics/genes/virology-receptors/tmprss2-gene-structure-function-pathway)